Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Breast Neoplasms 36Neoplasms 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasm Metastasis 5Pancreatic Neoplasms 4Ovarian Neoplasms 3Lymphoma, Mantle-Cell 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Advanced Breast Cancer 3Sarcoma 2Recurrence 2Prostatic Neoplasms 2Multiple Myeloma 2Melanoma 2Lymphoma, Non-Hodgkin 2Inflammation 2Hereditary Sensory and Autonomic Neuropathies 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thrombosis 1Thromboembolism 1Thrombocytosis 1Squamous Cell Carcinoma of Head and Neck 1Primary Myelofibrosis 1Oligodendroglioma 1Neoplasms, Neuroepithelial 1Myeloproliferative Disorders 1

Interventions

palbociclib 1mirdametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × KRAS Mutant Non-Small Cell Lung Cancer × palbociclib × Clear all
NCT02022982 2024-03-19

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

Dana-Farber Cancer Institute

Phase 1 Completed
60 enrolled
Other solid neoplasmThoracic

KRAS Mutant Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡